IRVINE, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Smart Health Diagnostics Company today announced that Sarah Barry has been appointed Lead Controller, assuming full leadership of the Company’s finance function as it enters its commercial stage. In this role, Ms. Barry will oversee all financial operations and reporting across Smart Health Diagnostics Company and its portfolio of companies, including MUSE Microscopy, Inc., MorningStar Laboratories, LLC, and the Company’s newly launched veterinary initiatives.
Ms. Barry has been a key financial contributor to the Company for several years, playing a vital role in resolving legacy complexities and helping reposition the organization for long-term growth. Her deep understanding of the Company’s operations and financial systems—combined with her extensive experience in corporate finance—makes her ideally suited to lead this next phase of financial oversight and growth strategy.
“We welcome Sarah to this role as we make the critical transition to revenue generation across all business channels,” said Larry Dentice, CEO of Smart Health Diagnostics Company.
She succeeds Tina Senter, who has played an exceptional role in stabilizing and advancing the Company’s financial operations. “Tina has been phenomenal in helping position us for this next chapter,” said Mr. Dentice. “We are deeply grateful for her dedication and impact during a critical time in our journey.”
“Sarah’s appointment is a pivotal step as we transition into a commercial-stage enterprise,” added Matthew Nunez, President of Smart Health Diagnostics Company. “Her leadership and commitment will bring continuity, clarity, and the strategic financial guidance needed to support growth across our business lines.” Ms. Barry’s appointment became effective November 1, 2025.
About Smart Health Diagnostics Company
Smart Health Diagnostics Company is a Delaware-based health innovation platform focused on precision diagnostics and next-generation laboratory services. Through its subsidiaries and initiatives—including MUSE Microscopy, Inc., MorningStar Laboratories, LLC, and its newly launched veterinary division—the Company is advancing a new era of accessible, accurate, and scalable diagnostic solutions.
Forward-Looking Statements
Forward-looking statements in this press release are based on our future expectations, plans prospects, and assumptions regarding matters that are not historical facts, may constitute “forward-looking statements” within the meaning of The Private Securities Litigation Reform Act of 1995. The words “termed,” “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks, and changes in circumstances that are difficult to predict. Our actual results may differ materially from those contemplated by the forward-looking statements. Therefore, we caution you against relying on any of these forward-looking statements. They are neither statements of historical fact nor guarantees or assurances of future performance.
Any forward-looking statement made by us in this document speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments, or otherwise, except as may be required by law.
Media Contact
mjjohnson@smarthealthdx.com
866.299.8998
